| AMA | 1) Anti-Mitochondrial Antibodies 2) American Medical Association |
|---|---|
| Anti-LKM | Antibodies to Liver-Kidney Microsome |
| FA | 1) Fatty Acid 2) Fluorescent Antibodies; 형광 항체 |
| MAbs | Monoclonal Antibodies |
| MHA-TP | Micro-Hemagglutination Assay for antibodies to Treponema Pallidum |
| C | Catalytic |
|---|---|
| DNA-PKcs | DNA-PK catalytic sub-unit |
| DNA-PKCS | DNA-dependent protein kinase catalytic subunit |
| hTERT | Human telomerase catalytic subunit |
| MCP | Multi-Catalytic Proteinase |
| antibodies, catalytic | Antibodies that can catalyze a wide variety of chemical reactions. They are characterised by high substrate specificity and share many mechanistic features with enzymes. (12 Dec 1998) |
|---|
| catalytic | Relating to or effecting catalysis. (05 Mar 2000) |
|---|---|
| catalytic antibody | <chemistry> Antibody raised against a transition state analogue (e.g. A phosphate analogue of a carboxylic acid ester transition state) that can then catalyse the analogous chemical reaction, though not as effectively as a true enzyme. (16 Mar 1998) |
| catalytic centre | See: active centre. (05 Mar 2000) |
| catalytic model | <epidemiology> A (rather misleading name for a) type of compartmental model in which the force of infection is treated as a parameter to be estimated. (05 Dec 1998) |
| catalytic site | <chemistry> The site on an enzyme where the substrate or substrates (the reactants of a chemical or biochemical reaction) attach in order to convert to the product or products of the reaction, at a much higher speed than the substrate would need to convert to the product alone. (16 Mar 1998) |
| RNA, catalytic | RNA which contains an intron sequence that has an enzyme-like catalytic activity. This intron sequence has been shown to fold up to form a complex surface that can function like an enzyme in reactions with other RNA molecules and thus synthesise new molecules even in the absence of protein. (12 Dec 1998) |
| acetylcholine receptor antibodies | <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream. Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission. Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy. AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis. AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis. Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis. Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued. Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears. (29 Dec 1997) |
| antibodies | Any of numerous protein molecules produced by the B-cells as a primary immune defense. (16 Dec 1997) |
| antibodies, anticardiolipin | Antiphospholipid antibodies found in association with systemic lupus erythematosus (lupus erythematosus, systemic), antiphospholipid syndrome, and in a variety of other diseases as well as in healthy individuals. The antibodies are detected by solid-phase immunoassay employing the purified phospholipid antigen cardiolipin. (12 Dec 1998) |
| antibodies, anti-idiotypic | Antibodies which react with the individual structural determinants (idiotopes) on the variable region of other antibodies. (12 Dec 1998) |
| antibodies, antineutrophil cytoplasmic | Autoantibodies directed against cytoplasmic constituents of polymorphonuclear leukocytes and/or monocytes. They are used as specific markers for wegener's granulomatosis and other diseases, though their pathophysiological role is not clear. Anca are routinely detected by indirect immunofluorescence with three different patterns: c-anca (cytoplasmic), p-anca (perinuclear), and atypical anca. (12 Dec 1998) |
| antibodies, antinuclear | See: Antinuclear antibodies. (12 Dec 1998) |
| antibodies, antiphospholipid | Autoantibodies directed against phospholipids. These antibodies are characteristically found in patients with systemic lupus erythematosus (lupus erythematosus, systemic), antiphospholipid syndrome, related autoimmune diseases, some non-autoimmune diseases, and also in healthy individuals. (12 Dec 1998) |
| antibodies, archaeal | Immunoglobulins induced by substances elaborated by archaea that have an antigenic activity. (12 Dec 1998) |
| antibodies, bacterial | Immunoglobulins induced by substances elaborated by bacteria that have an antigenic activity. (12 Dec 1998) |
Synonyms : Antibody, Catalytic, Catalytic Antibody
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|